Payment overview · 2025
General Payments
$470.47
33 reported records · 10 companies
Healthcare provider profile · identity verified
Aasia Butt, M.D
Allopathic & Osteopathic Physicians|Internal Medicine · JACKSON, OH · NPI 1053721803
Verified facts
What the public records show
CMS Open Payments records show Aasia Butt, M.D received $470.47 in general payments during 2025 across 33 reported records.
ABBVIE INC. accounted for 37.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $176.16 | 37.4% | 15 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $117.70 | 25.0% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $31.78 | 6.8% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $28.83 | 6.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $28.32 | 6.0% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $28.30 | 6.0% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.49 | 3.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.14 | 3.2% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.09 | 3.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.66 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $470.47 | 33 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $126.79 | 10 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $117.70 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $49.37 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $49.37 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $31.78 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $28.32 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $28.32 | 2 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $16.49 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.16 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.14 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $14.09 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.05 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $13.67 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $13.66 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $13.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
53 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
48 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
109 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 476 | 140 |
| Levothyroxine Sodium | Levothyroxine Sodium | 411 | 110 |
| Amlodipine Besylate | Amlodipine Besylate | 369 | 117 |
| Metoprolol Succinate | Metoprolol Succinate | 353 | 96 |
| Omeprazole | Omeprazole | 348 | 93 |
| Lisinopril | Lisinopril | 344 | 87 |
| Furosemide | Furosemide | 308 | 105 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 306 | 96 |
| Losartan Potassium | Losartan Potassium | 285 | 79 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 276 | 78 |
| Gabapentin | Gabapentin | 268 | 59 |
| Metoprolol Tartrate | Metoprolol Tartrate | 232 | 55 |
| Sertraline Hcl | Sertraline Hcl | 226 | 51 |
| Fluticasone Propionate | Fluticasone Propionate | 220 | 85 |
| Prednisone | Prednisone | 209 | 107 |
| Metformin Hcl | Metformin Hcl | 192 | 56 |
| Famotidine | Famotidine | 190 | 62 |
| Tizanidine Hcl | Tizanidine Hcl | 184 | 76 |
| Potassium Chloride | Potassium Chloride | 183 | 60 |
| Eliquis | Apixaban | 179 | 36 |
| Buspirone Hcl | Buspirone Hcl | 170 | 47 |
| Montelukast Sodium | Montelukast Sodium | 168 | 50 |
| Pravastatin Sodium | Pravastatin Sodium | 165 | 46 |
| Azithromycin | Azithromycin | 154 | 105 |
| Duloxetine Hcl | Duloxetine Hcl | 146 | 46 |
| Metformin Hcl Er | Metformin Hcl | 144 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 143 | 46 |
| Glimepiride | Glimepiride | 141 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 137 | 43 |
| Trazodone Hcl | Trazodone Hcl | 136 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 133 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 124 | 39 |
| Alendronate Sodium | Alendronate Sodium | 121 | 29 |
| Simvastatin | Simvastatin | 117 | 34 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 109 | 25 |
| Ozempic | Semaglutide | 109 | 19 |
| Jardiance | Empagliflozin | 107 | 20 |
| Allopurinol | Allopurinol | 103 | 25 |
| Ibuprofen | Ibuprofen | 103 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 102 | 37 |
| Trulicity | Dulaglutide | 102 | 22 |
| Ezetimibe | Ezetimibe | 95 | 30 |
| Citalopram Hbr | Citalopram Hydrobromide | 92 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 88 | 22 |
| Meloxicam | Meloxicam | 87 | 27 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 85 | 27 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 80 | 24 |
| Ondansetron Hcl | Ondansetron Hcl | 79 | 35 |
| Valsartan | Valsartan | 76 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 74 | 22 |
| Fluconazole | Fluconazole | 73 | 31 |
| Ropinirole Hcl | Ropinirole Hcl | 73 | 21 |
| Cephalexin | Cephalexin | 71 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 70 | 21 |
| Mounjaro | Tirzepatide | 70 | suppressed |
| Spironolactone | Spironolactone | 70 | 18 |
| Lorazepam | Lorazepam | 69 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 68 | 21 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 68 | 18 |
| Tramadol Hcl | Tramadol Hcl | 68 | 15 |
| Breo Ellipta | Fluticasone/Vilanterol | 66 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 66 | 44 |
| Doxycycline Hyclate | Doxycycline Hyclate | 65 | 43 |
| Nystatin | Nystatin | 63 | 29 |
| Fluoxetine Hcl | Fluoxetine Hcl | 61 | 17 |
| Lovastatin | Lovastatin | 61 | 20 |
| Donepezil Hcl | Donepezil Hcl | 59 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 58 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 57 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 56 | 20 |
| Dicyclomine Hcl | Dicyclomine Hcl | 56 | 24 |
| Pregabalin | Pregabalin | 53 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 53 | 16 |
| Finasteride | Finasteride | 52 | 13 |
| Glipizide Er | Glipizide | 52 | 15 |
| Carvedilol | Carvedilol | 51 | 18 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 50 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 49 | 21 |
| Oxybutynin Chloride | Oxybutynin Chloride | 49 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 49 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 48 | 11 |
| Ondansetron Odt | Ondansetron | 47 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 47 | 25 |
| Methocarbamol | Methocarbamol | 46 | 13 |
| Atenolol | Atenolol | 45 | 14 |
| Ketoconazole | Ketoconazole | 45 | 20 |
| Xarelto | Rivaroxaban | 45 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 44 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 44 | 12 |
| Meclizine Hcl | Meclizine Hcl | 42 | 19 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 42 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 41 | 31 |
| Ventolin Hfa | Albuterol Sulfate | 41 | 15 |
| Januvia | Sitagliptin Phosphate | 38 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 35 | 17 |
| Alprazolam | Alprazolam | 35 | suppressed |
| Celecoxib | Celecoxib | 35 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 35 | 13 |
| Glipizide | Glipizide | 35 | 12 |
| Lidocaine | Lidocaine | 35 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 35 | 12 |
| Spiriva Respimat | Tiotropium Bromide | 35 | suppressed |
| Synthroid | Levothyroxine Sodium | 35 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 34 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 33 | suppressed |
| Fenofibrate | Fenofibrate | 32 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 31 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 30 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 30 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 29 | 11 |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 28 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 27 | suppressed |
| Topiramate | Topiramate | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Lactulose | Lactulose | 26 | suppressed |
| Naproxen | Naproxen | 26 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 26 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 26 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 25 | suppressed |
| Novolog Flexpen | Insulin Aspart | 25 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 25 | suppressed |
| Klor-Con M20 | Potassium Chloride | 24 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 24 | suppressed |
| Nabumetone | Nabumetone | 23 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 22 | suppressed |
| Entresto | Sacubitril/Valsartan | 22 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 21 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 21 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 20 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Folic Acid | Folic Acid | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | 13 |
| Rybelsus | Semaglutide | 19 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 17 | suppressed |
| Constulose | Lactulose | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Prazosin Hcl | Prazosin Hcl | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Kerendia | Finerenone | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 12 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 11 | suppressed |
| Amlodipine-Valsartan-Hctz | Amlodipine/Valsartan/Hcthiazid | 11 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $470.47 · 33 records | ABBVIE INC. | AIRSUPRA, AREXVY, Cologuard Collection Kit, Dexcom G6 Transmitter, OTEZLA, QULIPTA, RECORLEV, REPATHA, REXULTI, SHINGRIX, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, Wegovy, XIFAXAN | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error